.png)
This week the Eyes on Pharma team was, like you, reviewing all of the results & guidance news – whew! But we still found a few other topics trending we thought you might be interested in. Check out the latest on some of the Opioid Litigation, SPACS, and yes two Top 10 Lists! See below for the tidbits from the week ending 20 Feb.
Results. Results. Results. Though many firms messaged their results early with preliminary announcements – The Annual or Semi-Annual results and Guidance were hot topics again last week. PharmaTell Studio clients can use search terms such as “2022 Guidance” + [Company name or ticker] in the general search area to see Intel about you and your competition.
Opioids The distributors – AmerisourceBergen, Cardinal Health, & McKesson – announced that each company is moving forward with the opioid settlement. This was expected and removes some overhang for the firms as 46 of 49 states + DC and all eligible territories are participating. The deal is expected to be final in April 2022. For clients more details can be found here and here
SPACs As the market volatility continues – more news trickles in about the not-so-good fate of SPACs in the healthcare sector – predominantly Biotech. The latest is a potential spin-off of gene therapy business from Amicus that was scrapped. Plus, late last year a deal between AI-drug discovery group Valo Health and a Khosla Ventures SPAC was called off at the last minute see article here. With the Bear market and a poor track record in general, this is a space to watch in 2022.
Top Sellers We love lists – and so do the folks at Evaluate. Their Vantage report shares 2 list this week – check out Biopharma’s Top Sellers Forecast Thru 2026 and Their Top 10 Launches for 2022!
Tip of the Week Don’t forget you can refine your searches in the catalogues by using the SEARCH box in the upper right to add more search terms. This is similar to the Google advanced search feature. More details are on the Help page